Prasugrel News and Research

RSS

SWITCH SWEDEHEART trial shows prasugrel matches ticagrelor with less bleeding

Prasugrel reduced major cardiovascular events to the same extent as ticagrelor but with lower major bleeding after coronary stenting in patients with acute coronary syndromes, according to results from the SWITCH SWEDEHEART trial presented in a Hot Line session today at ESC Congress 2026 and published simultaneously in the New England Journal of Medicine.

29 Aug 2026

Trial findings do not support prasugrel monotherapy at the time of primary PCI for STEMI patients

Monotherapy using prasugrel failed to show noninferiority compared with potent antiplatelet therapy plus aspirin at the time of primary percutaneous coronary intervention for ST-segment elevation myocardial infarction.

29 Aug 2026

Potent antiplatelet therapy increases bleeding risk after heart attack in AF patients

Potent antiplatelet therapy increased bleeding without signs of benefit regarding cardiovascular events in patients with atrial fibrillation after a heart attack.

29 Aug 2026

New protein discovery could lead to safer antithrombotic therapies

Antiplatelet drugs are one of the main tools used to prevent thrombus formation in people who have had a heart attack or stroke or who have cardiovascular diseases with a high thrombotic risk.

17 Jun 2026

Antiplatelet medications linked to worse outcomes in people hospitalized with a brain bleed

Analysis of hospital registry data found that people who were hospitalized due to bleeding in the brain and who had taken multiple antiplatelet medications, or medications stronger than aspirin, were more likely to die before leaving the hospital compared to those not taking any antiplatelet medication, according to a preliminary study to be presented at the American Stroke Association's International Stroke Conference 2026.

29 Jan 2026

One-month dual therapy strategy offers advantages for AFib patients and clinicians

New research found a simplified clot-preventing medication regimen following stent placement in adults with atrial fibrillation was just as safe and effective in preventing strokes, heart attack and death, when compared to a standard year-long treatment regimen, according to a preliminary late-breaking science presentation today at the American Heart Association's Scientific Sessions 2025.

11 Nov 2025

Comparative study finds higher rates of adverse events with ticagrelor

One year of treatment with either of two strong blood-thinning medications—ticagrelor and prasugrel—by people with type 1 or type 2 diabetes who had a drug-eluting stent placed in their heart to treat coronary artery blockages did not offer the same level of benefit to prevent stent clotting, heart attacks, and bleeding complications, according to findings presented during a preliminary late-breaking science session during the American Heart Association's Scientific Sessions 2025 in New Orleans on November 10.

10 Nov 2025

Prasugrel shows advantage over ticagrelor in diabetic patients after stent placement

One year of dual antiplatelet therapy with one of two potent P2Y12 inhibitors-ticagrelor or prasugrel-in people with Type 1 or Type 2 diabetes who had received a drug-eluting stent did not offer the same level of benefit at preventing stent clotting, heart attacks and bleeding complications, according to a preliminary late-breaking science presentation today at the American Heart Association's Scientific Sessions 2025.

10 Nov 2025

Trial compares the use of blood thinners after stenting in patients with acute coronary syndromes

Noninferiority was not demonstrated for death and ischemic events between P2Y12 inhibitor monotherapy and dual antiplatelet therapy (DAPT) given for 12 months after stenting in patients with acute coronary syndromes (ACS), according to late-breaking research presented in a Hot Line session today at ESC Congress 2025 and simultaneously published in New England Journal of Medicine.

3 Sep 2025

Study shows reduced bleeding risk with ticagrelor monotherapy after percutaneous coronary intervention

People who have had a heart attack or who are at risk for a heart attack and who stopped taking aspirin alongside the P2Y12 inhibitor ticagrelor one month after undergoing percutaneous coronary intervention (PCI) saw a significantly reduced risk of clinically meaningful bleeding with no increased risk of clotting-related adverse events at 12 months compared with patients who continued taking aspirin and ticagrelor for a full year, in a study presented at the American College of Cardiology's Annual Scientific Session.

8 Apr 2024

Study: Most stroke survivors can safely take two types of common antidepressants

Most stroke survivors were able to safely take two types of common antidepressants, according to a preliminary study to be presented at the American Stroke Association's International Stroke Conference 2024.

1 Feb 2024

Dual-antiplatelet therapy should remain the standard strategy for PCI even in the drug-eluting stent era

Prasugrel monotherapy after percutaneous coronary intervention (PCI) with drug-eluting stents is not superior to dual-antiplatelet therapy (DAPT) for major bleeding but is non-inferior for cardiovascular events in patients with acute coronary syndrome (ACS) or high bleeding risk (HBR), according to late breaking research presented in a Hot Line session today at ESC Congress 2023.

28 Aug 2023

What are the long-term outcomes of critical COVID-19 patients?

Researchers assessed the long-term outcomes of critically ill coronavirus disease 2019 (COVID-19) patients.

21 Dec 2022

Identifying and managing drug-drug interactions key to the safe use of nirmatrelvir–ritonavir in COVID-19 treatment

Researchers compiled evidence-based recommendations in consultation with European and North American clinicians and pharmacologists for recognizing and managing drug-drug interactions with nirmatrelvir–ritonavir.

3 Mar 2022

Precision medicine can determine the best drug treatment for severe heart disease

Is personalized medicine cost-effective? University of Alabama at Birmingham researcher Nita Limdi, Pharm.D., Ph.D., and colleagues across the United States have answered that question for one medical treatment.

15 May 2020

Study indicates the benefits of stopping aspirin in heart attack patients

Patients who stopped taking aspirin three months after receiving a stent to open the heart's arteries but continued taking a P2Y12inhibitor—clopidogrel, prasugrel or ticagrelor—did not experience higher rates of death from any cause, heart attack or stroke after a year compared with those receiving standard therapy, according to research presented at the American College of Cardiology's 68thAnnual Scientific Session.

19 Mar 2019

Access to real-time genotype data influences prescriber behavior after PCI

Today, in a late-breaking featured clinical research session at the American College of Cardiology Scientific Sessions 2018, researchers from Penn Medicine present first-of-its-kind data on the impact of real-time CYP2C19 genotype results when prescribing antiplatelet drugs in the clinic.

13 Mar 2019

Study aims to understand role of clopidogrel in patients with cardiovascular disease

Platelet inhibition with aspirin is the cornerstone of medical therapy for coronary artery disease. In the era of percutaneous coronary intervention with drug-eluting stents, dual anti-platelet therapy with the addition of clopidogrel became the mainstay of therapy.

11 Sep 2018

New ESC Focused Update provides recommendations on DAPT in patients with coronary artery disease

The first ESC Focused Update on Dual Antiplatelet Therapy in Coronary Artery Disease is published online today in European Heart Journal, and on the ESC website.

26 Aug 2017

Platelet function testing in elderly patients after heart attack shows no improved outcomes

Monitoring platelet function in order to individualize antiplatelet therapy did not improve outcomes for elderly patients after a heart attack compared to a standard, unmonitored approach, results of the ANTARCTIC trial show.

29 Aug 2016

Prasugrel News and Research

SWITCH SWEDEHEART trial shows prasugrel matches ticagrelor with less bleeding

Trial findings do not support prasugrel monotherapy at the time of primary PCI for STEMI patients

Potent antiplatelet therapy increases bleeding risk after heart attack in AF patients

New protein discovery could lead to safer antithrombotic therapies

Antiplatelet medications linked to worse outcomes in people hospitalized with a brain bleed

One-month dual therapy strategy offers advantages for AFib patients and clinicians

Comparative study finds higher rates of adverse events with ticagrelor

Prasugrel shows advantage over ticagrelor in diabetic patients after stent placement

Trial compares the use of blood thinners after stenting in patients with acute coronary syndromes

Study shows reduced bleeding risk with ticagrelor monotherapy after percutaneous coronary intervention

Study: Most stroke survivors can safely take two types of common antidepressants

Dual-antiplatelet therapy should remain the standard strategy for PCI even in the drug-eluting stent era

What are the long-term outcomes of critical COVID-19 patients?

Identifying and managing drug-drug interactions key to the safe use of nirmatrelvir–ritonavir in COVID-19 treatment

Precision medicine can determine the best drug treatment for severe heart disease

Study indicates the benefits of stopping aspirin in heart attack patients

Access to real-time genotype data influences prescriber behavior after PCI

Study aims to understand role of clopidogrel in patients with cardiovascular disease

New ESC Focused Update provides recommendations on DAPT in patients with coronary artery disease

Platelet function testing in elderly patients after heart attack shows no improved outcomes

Industry Focus eBook - Neurology/Neuroscience - 2nd edition eBook

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News